Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 338 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Welcome to our new committee chairs November 22, 2022 FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer November 8, 2023 Young District Attorney Diagnosed with Breast Cancer Encourages Others to Get... November 30, 2020 Two Early Studies Show Rapid Antitumour CAR-Mediated Responses, but Often of... March 20, 2024 Load more HOT NEWS Cancer Rehabilitation Starts at Diagnosis: Part II Preliminary Evidence of Efficacy of an Upfront ICI-based Therapeutic Strategy in... FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... FDA Approves Nivolumab in Combination with Chemotherapy and Nivolumab in Combination...
